Search Results

You are looking at 191 - 200 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes

subtypes may occur. The less common ovarian histopathologies (LCOHs) include carcinosarcomas (malignant mixed Müllerian tumors [MMMTs] of the ovary), clear cell carcinomas, mucinous carcinomas, grade 1 (low-grade) serous carcinomas/endometrioid epithelial

Full access

Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

Uterine Neoplasms Adenocarcinoma of the endometrium (also known as endometrial cancer , or more broadly as uterine cancer or carcinoma of the uterine corpus ) is the most common malignancy of the female genital tract in the United States. It is

Full access

Kidney Cancer, Version 3.2015

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

. Overview Renal cell carcinoma (RCC) constitutes approximately 3.9% of new cancers, with a median age of 64 years at diagnosis. The American Cancer Society estimated that 63,920 Americans would be diagnosed with and 13,860 would die of RCC in the United

Full access

CLO24-071: A Propensity Matched Survival Analysis Comparing Partial Versus Radical Nephrectomy in Patients with Metastatic Renal Cell Carcinoma: A National Cancer Database Study

Nathan VanderVeer-Harris, Aden Swayze, Ronscardy Mondesir, Raghuram Reddy, Pushan Prabhakar, Arjun Pon Avudaiappan, Ahmed Eldefrawy, Murugesan Manoharan, and Jorge Caso

Introduction: At the time of diagnosis, renal cell carcinoma can present with metastases in 25%–30% of cases. In carefully selected individuals cytoreductive surgery (partial or radical nephrectomy) can be beneficial. In such cases, radical

Full access

CLO23-064: PD-1/PD-L1 Inhibitors in Advanced and Metastatic Esophageal Carcinoma: An Updated Meta-Analysis of Randomized Controlled Trials

Akshit Chitkara, Femina Patel, Rushin Patel, FNU Anamika, and Rajat Thawani

performed by three authors independently. We screened PubMed, Embase, and Cochrane databases for randomized controlled phase III trials or meta-analyses investigating the effects of the anti-PD-1/PD-L1 immune checkpoint therapy in esophageal carcinoma. The

Full access

Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer

Michael Xiang and Elizabeth A. Kidd

cervical squamous cell carcinoma or adenocarcinoma. Cases were included from 2004 and onward, when modern staging information became available in SEER. Patients with unknown FIGO stage or nodal stage were excluded. To ensure adequate capture of claims and

Full access

Biomarker Testing for Immunotherapy

Jarushka Naidoo

carcinoma and metastatic melanoma, all patients should receive immune checkpoint blockade, regardless of a biomarker, Dr. Naidoo said. “But this is a rapidly evolving space, and it's likely to change every couple of months in reality,” she added. Inflamed

Full access

Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study

Brigette A. Davis, Jenerius A. Aminawung, Maysa M. Abu-Khalaf, Suzanne B. Evans, Kevin Su, Rajni Mehta, Shi-Yi Wang, and Cary P. Gross

) invasive breast cancer irrespective of tumor size. Based on the 2009 guidelines, women with 1 to 3 positive axillary nodes were considered guideline-discordant. We excluded patients with ductal carcinoma in situ, localized HR+, node-negative, ≤5 mm

Full access

Genomic Testing in Lung Cancer: Past, Present, and Future

Céline Mascaux, Ming-Sound Tsao, and Fred R. Hirsch

rearrangements, and ROS1 fusions using the most accessible tissue (primary tumor or metastasis). These guidelines also state that testing can be considered in patients with pure squamous cell carcinoma (SCC) with clinical features that are associated with a

Full access

HSR24-123: High Dose Rate Interstitial Brachytherapy for Squamous Cell Carcinoma of the Vagina: Methods and Outcomes at a Single Institution

Jonathan C. Bastick III, Andrés Portocarrero Bonifaz, Bryce Forry, Maxwell Kassel, Salman Syed, Grant W. McKenzie, Keith T. Sowards, Jeremy T. Gaskins, and Scott R. Silva

Background: Due to the rarity of the disease, limited data exists regarding treatment for squamous cell carcinoma (SCC) of the vagina. Our goal was to evaluate the toxicity and outcomes of vaginal cancer patients treated with external beam